

May 30, 2013

## **ImmunoGen, Inc. Announces Webcast of Presentations at Upcoming Investor Conferences**

WALTHAM, Mass.--(BUSINESS WIRE)-- [ImmunoGen, Inc.](http://www.immunogen.com) (Nasdaq: IMGN), a biotechnology company that develops anticancer therapeutics using its Targeted Antibody Payload (TAP) antibody-drug conjugate (ADC) technology, today announced that the following presentations by Company management at upcoming investor conferences will be webcast:

- **Jefferies 2013 Global Healthcare Conference**  
11:30 am ET, June 5, 2013 in New York, NY  
Presenter: Daniel Junius, President and CEO
- **Goldman Sachs 34<sup>th</sup> Annual Global Healthcare Conference**  
9:20 am PT, June 13, 2013 in Rancho Palos Verdes, CA  
Presenter: Gregory Perry, Executive Vice President and CFO

The webcasts will be accessible live through the "Investor Information" section of the Company's website, [www.immunogen.com](http://www.immunogen.com); a replay will be available at the same location for approximately a week.

### **About ImmunoGen, Inc.**

ImmunoGen, Inc. develops targeted anticancer therapeutics. The Company's TAP technology uses a tumor-targeting monoclonal antibody to deliver one of ImmunoGen's highly potent cancer cell-killing agents specifically to tumor cells. Ten TAP compounds are now in the clinic, of which three are wholly owned by the Company. The most advanced compound using ImmunoGen's TAP technology, Kadcyla<sup>TM</sup>, has been approved for marketing in the US and Switzerland, and is undergoing regulatory review in the European Union and Japan. Kadcyla is being commercialized in the US by Genentech, a member of the Roche Group. More information about ImmunoGen can be found at [www.immunogen.com](http://www.immunogen.com).

Kadcyla<sup>TM</sup> is a trademark of Genentech.

For Investors:  
ImmunoGen, Inc.  
Carol Hausner, 781-895-0600  
Executive Director, Investor Relations and Corporate Communications  
[info@immunogen.com](mailto:info@immunogen.com)

or

For Media:  
The Yates Network  
Barbara Yates, 781-258-6153

Source: ImmunoGen, Inc.

News Provided by Acquire Media